154 related articles for article (PubMed ID: 11982649)
21. Valacyclovir to reduce transmission of genital herpes simplex virus infection.
Drew WL
J Infect Dis; 2009 Mar; 199(6):916. PubMed ID: 19239344
[No Abstract] [Full Text] [Related]
22. Does frequency of genital herpes recurrences predict risk of transmission? Further analysis of the valacyclovir transmission study.
Kim HN; Wald A; Harris J; Almekinder J; Heitman C; Corey L
Sex Transm Dis; 2008 Feb; 35(2):124-8. PubMed ID: 17921912
[TBL] [Abstract][Full Text] [Related]
23. Effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice: how dissimilar are study results?
Thackray AM; Field HJ
J Infect Dis; 2000 Apr; 181(4):1517-8. PubMed ID: 10762588
[No Abstract] [Full Text] [Related]
24. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
[TBL] [Abstract][Full Text] [Related]
25. Photo quiz. 21-Year-old male trauma patient with skin and liver lesions, hepatitis, and coagulopathy.
Alao O; Crothers BA; Ressner R
Clin Infect Dis; 2013 Feb; 56(4):559, 613-4. PubMed ID: 23345643
[No Abstract] [Full Text] [Related]
26. HSV shedding.
Sacks SL; Griffiths PD; Corey L; Cohen C; Cunningham A; Dusheiko GM; Self S; Spruance S; Stanberry LR; Wald A; Whitley RJ
Antiviral Res; 2004 Aug; 63 Suppl 1():S19-26. PubMed ID: 15450382
[TBL] [Abstract][Full Text] [Related]
27. [Perspectives for the treatment and prevention of herpes simplex infections].
Snoeck R
Ann Dermatol Venereol; 2002 Apr; 129(4 Pt 2):662-5. PubMed ID: 12122338
[No Abstract] [Full Text] [Related]
28. Suppressive valacyclovir therapy: impact on the population spread of HSV-2 infection.
Williams JR; Jordan JC; Davis EA; Garnett GP
Sex Transm Dis; 2007 Mar; 34(3):123-31. PubMed ID: 17325600
[TBL] [Abstract][Full Text] [Related]
29. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences: A Randomized Clinical Trial.
Wald A; Timmler B; Magaret A; Warren T; Tyring S; Johnston C; Fife K; Selke S; Huang ML; Stobernack HP; Zimmermann H; Corey L; Birkmann A; Ruebsamen-Schaeff H
JAMA; 2016 Dec; 316(23):2495-2503. PubMed ID: 27997653
[TBL] [Abstract][Full Text] [Related]
30. Successors to acyclovir.
Easterbrook P; Wood MJ
J Antimicrob Chemother; 1994 Sep; 34(3):307-11. PubMed ID: 7829405
[No Abstract] [Full Text] [Related]
31. Herpes simplex virus (HSV)-suppressive therapy decreases plasma and genital HIV-1 levels in HSV-2/HIV-1 coinfected women: a randomized, placebo-controlled, cross-over trial.
Baeten JM; Strick LB; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Magaret A; Wald A; Corey L; Celum C
J Infect Dis; 2008 Dec; 198(12):1804-8. PubMed ID: 18928378
[TBL] [Abstract][Full Text] [Related]
32. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
[TBL] [Abstract][Full Text] [Related]
33. A pilot study examining the safety and tolerability of valacyclovir in veterans with hepatitis C virus/herpes simplex virus type 2 coinfection.
Burton MJ; Penman A; Sunesara I; McGuire BM; Hook EW
Am J Med Sci; 2014 Dec; 348(6):455-9. PubMed ID: 25163019
[TBL] [Abstract][Full Text] [Related]
34. Herpes simplex vegetans presenting as an eyelid mass.
Blieden LS; Chévez-Barrios P; Yen MT
Ophthalmic Plast Reconstr Surg; 2011; 27(3):e58-9. PubMed ID: 20829726
[TBL] [Abstract][Full Text] [Related]
35. Herpes treatment may limit HIV transmission and progression.
Wilkinson E
Lancet Infect Dis; 2007 Apr; 7(4):249. PubMed ID: 17419138
[No Abstract] [Full Text] [Related]
36. Can herpes simplex virus type 2 suppression slow HIV disease progression: a study protocol for the VALacyclovir In Delaying Antiretroviral Treatment Entry (VALIDATE) trial.
Tan DH; Raboud JM; Kaul R; Grinsztejn B; Cahn P; Walmsley SL
Trials; 2010 Nov; 11():113. PubMed ID: 21106086
[TBL] [Abstract][Full Text] [Related]
37. Valacyclovir versus acyclovir for HSV prophylaxisin neutropenic patients.
Warkentin DI; Epstein JB; Campbell LM; Yip JG; Cox VC; Ransier A; Barnett MJ; Marra F
Ann Pharmacother; 2002 Oct; 36(10):1525-31. PubMed ID: 12243600
[TBL] [Abstract][Full Text] [Related]
38. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial.
Kimberlin D; Powell D; Gruber W; Diaz P; Arvin A; Kumar M; Jacobs R; Van Dyke R; Burchett S; Soong SJ; Lakeman A; Whitley R
Pediatr Infect Dis J; 1996 Mar; 15(3):247-54. PubMed ID: 8852914
[TBL] [Abstract][Full Text] [Related]
39. Valacyclovir for the prevention of recurrent herpes simplex virus eye disease after excimer laser photokeratectomy.
Asbell PA
Trans Am Ophthalmol Soc; 2000; 98():285-303. PubMed ID: 11190029
[TBL] [Abstract][Full Text] [Related]
40. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy.
Eisen D; Essell J; Broun ER; Sigmund D; DeVoe M
Bone Marrow Transplant; 2003 Jan; 31(1):51-5. PubMed ID: 12621507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]